Indoco Remedies (INDOCO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Indoco Remedies (INDOCO) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹2,149 Crore, trading at ₹233.20 on the NSE. This SniperIQ fundamentals page covers Indoco Remedies's valuation, profitability (net margin -5.3%), revenue (₹1,845 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Indoco Remedies's market cap?
Indoco Remedies (INDOCO) has a market capitalization of approximately ₹2,149 Crore, trading at ₹233.20 on the NSE. Market cap moves with the live share price.
What is Indoco Remedies's P/E ratio?
Indoco Remedies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Indoco Remedies?
Indoco Remedies runs a net profit margin of -5.3%, a gross margin of 54.9%, and an operating margin of 0.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Indoco Remedies generate?
Indoco Remedies reported revenue of ₹1,845 Crore for fiscal year 2026, with net income of -₹99 Crore and earnings per share (EPS) of -10.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Indoco Remedies pay a dividend?
Indoco Remedies offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Indoco Remedies financially healthy?
Indoco Remedies carries a debt-to-equity ratio of 1.16x and a current ratio of 1.13x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Indoco Remedies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Indoco Remedies (INDOCO) the key facts are: market cap ₹2,149 Crore, revenue ₹1,845 Crore, 52-week range 162.19-336. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Indoco Remedies's full fundamentals live
Get Indoco Remedies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.